Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

First line of the email MUST contain the NCT# and Site #.


BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Back

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Recruiting

Open to: ALL

Age: 18.0 - 60.0

Manchester Salford London London

Medical Conditions

Myasthenia Gravis
Muscle Weakness
Multiple Sclerosis
Sclerosis

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2024 Jul 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Administration of CC-97540 (MG arm);Administration of CC-97540 (PMS arm);Administration of CC-97540 (RMS arm);

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Administration of CC-97540 (MG arm);Administration of CC-97540 (PMS arm);Administration of CC-97540 (RMS arm);

Intervention Type : DRUG
Intervention Description : Specified dose on specified days

Intervention Arm Group : Administration of CC-97540 (MG arm);Administration of CC-97540 (PMS arm);Administration of CC-97540 (RMS arm);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Manchester Royal Infirmary
    Manchester
    M13 9WL
  • Salford Royal Hospital
    Salford
    Manchester
    M6 8HD
  • Local Institution - 0020
    London
    E1 1RD
  • University College London Hospital
    London
    London, City Of
    NW1 2PG

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com 855-907-3286
Clinical.Trials@bms.com


First line of the email MUST contain the NCT# and Site #.



The study is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and is in collaboration with Celgene Corporation.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06220201
Last updated 02 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top